Medical net June 29 the blood product industry does not lack "good play". In the past, we have been seeking to acquire the Asian blood products, Shanghai leishi. Now, there are also new developments in the ST biochemistry of blood products.
Today, ST biochemical announcement of the tender offer report, hangzhou, zhejiang people vote for celestica investment partnership (limited partnership) (hereinafter referred to as "zhejiang people celestica") plans to spend about $2.7 billion through the acquisition ST biochemical control.
Zhejiang private capital is targeted for control
The offer is part of the offer, with zhe tianhong's bid of $36 per share for a total of 74.92 million shares (27.49 per cent of the total).
The offer price has a certain amount of premium. In the 30 trading days before the announcement, the average daily weighted average price of ST biochemistry was 28.10 yuan per share, while the latest share price of ST biochemistry was 30.93 yuan per share.
According to the calculation, based on the premise that the offer price is 36 yuan per share, the total amount of the maximum funds required for this offer is close to 2.7 billion yuan.
Previously, tianhong did not own ST biochemical shares, but its consistent action people, zhe min and zhejiang min-invested enterprises, held a 2.51% stake in ST biochemistry. After the expiration of the tender offer, the people of zhe and its concerted actions will hold a maximum of 29.99 % of ST biochemistry.
According to the rules of tender offer, the ST biochemical first notice the tender offer report, the future for the full announcement after tender offer report, this offer will be officially stepped into the stage of implementation.
According to the disclosure, the executive affairs partner of zhe min tianhong is consulting for the people of zhejiang province, and the single shareholder of zhejiang people's investment advisory is zhe min. Zhejiang people vote for full name "zhejiang private enterprises joint investment co., LTD.", the background is a deep, consists of eight, including such as chint group, zhejiang private enterprises and institutions founded, made financial investment for a large joint-stock company, focus on financial services, health care, and energy conservation, environmental protection, advanced manufacturing and high-end equipment and the reform of state-owned enterprises, etc.
Blood products industry "hot"
The tongfang shares of the tsinghua department and zhejiang people's capital of zhejiang private capital are invested in the industry of the blood products industry, which has two blood products industry mergers and acquisitions in a week.
Zhejiang people said, it has the health care as one of strategic investments, has long been focused on biological pharmaceutical, precision medical, the Internet and the development of gene technology, in the process also formed a certain way of thinking, and have a special liking to blood products industry.
People in the industry believe that our country's blood products have been in severe shortage for a long time. With the development of the scope of clinical application and the increase of the aging population, the demand for blood liquid products is increasing. In addition, in the new edition of the health care catalog, the blood products reimbursement scope is expanded, and the future clinical demand is expected to continue to increase. Since the price of blood products was released in June 2015, China's blood products industry has entered a stage of rapid development. The group believes that consolidation of the industry will be a trend in the development of our blood products industry in the coming years.
It is in this context that the tsinghua department and zhejiang private capital have successively laid out the blood products industry.
ST biochemistry is a listed company that produces and sells blood products. Its 2016 annual report showed that the company realized revenue of 567 million yuan last year, up 13.43 percent and net profit of 5389.59 million yuan. The company took the blood products industry of shuanglin in guangdong as the focus of development, and the amount of pulp was 301.58 tons in 2016, which increased by 10.64%, and the plasma supply increased steadily.
According to the ST biochemical announcement, the acquirer and its concerted action people are optimistic about the development prospects of the blood products industry and the development potential of listed companies to take control of listed companies through this acquisition. At that time, the acquirer and the concerted action person will take advantage of their own resources to help listed companies improve management efficiency and promote stable development of listed companies.
This is also a good thing for ST biochemistry. In the past, ST biochemistry was burdened with heavy historical baggage, and it was difficult to take advantage of the listed company platform to facilitate the development of the main industry. According to the people's investment in zhejiang province, the offer to buy ST biochemistry is to practice the financial support of the real economy and promote the development of the industry. |
